BRPI1011940B8 - método de redobramento de uma proteína expressa em um sistema de expressão de não mamífero - Google Patents
método de redobramento de uma proteína expressa em um sistema de expressão de não mamíferoInfo
- Publication number
- BRPI1011940B8 BRPI1011940B8 BRPI1011940A BRPI1011940A BRPI1011940B8 BR PI1011940 B8 BRPI1011940 B8 BR PI1011940B8 BR PI1011940 A BRPI1011940 A BR PI1011940A BR PI1011940 A BRPI1011940 A BR PI1011940A BR PI1011940 B8 BRPI1011940 B8 BR PI1011940B8
- Authority
- BR
- Brazil
- Prior art keywords
- refolding
- expression system
- mammalian expression
- protein expressed
- concentration equal
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 230000030788 protein refolding Effects 0.000 abstract 1
- 239000006176 redox buffer Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21925709P | 2009-06-22 | 2009-06-22 | |
| US61/219,257 | 2009-06-22 | ||
| PCT/US2010/039390 WO2011005488A1 (en) | 2009-06-22 | 2010-06-21 | Refolding proteins using a chemically controlled redox state |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI1011940A2 BRPI1011940A2 (pt) | 2016-11-22 |
| BRPI1011940B1 BRPI1011940B1 (pt) | 2021-07-20 |
| BRPI1011940B8 true BRPI1011940B8 (pt) | 2021-08-03 |
Family
ID=42710673
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1011940A BRPI1011940B8 (pt) | 2009-06-22 | 2010-06-21 | método de redobramento de uma proteína expressa em um sistema de expressão de não mamífero |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US8952138B2 (enExample) |
| EP (2) | EP3366692A1 (enExample) |
| JP (2) | JP5808323B2 (enExample) |
| KR (1) | KR101741859B1 (enExample) |
| CN (1) | CN102482321B (enExample) |
| AU (1) | AU2010270986B2 (enExample) |
| BR (1) | BRPI1011940B8 (enExample) |
| CA (1) | CA2765881C (enExample) |
| CL (1) | CL2011003278A1 (enExample) |
| EA (1) | EA020621B1 (enExample) |
| IL (1) | IL216954A (enExample) |
| MX (1) | MX2011013898A (enExample) |
| SG (1) | SG176963A1 (enExample) |
| WO (1) | WO2011005488A1 (enExample) |
| ZA (1) | ZA201200512B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5808323B2 (ja) * | 2009-06-22 | 2015-11-10 | アムジエン・インコーポレーテツド | 化学的に制御されたレドックス状態を用いたタンパク質のリフォールディング |
| EP3660032B1 (en) | 2009-06-25 | 2025-10-22 | Amgen Inc. | Capture purification processes for proteins expressed in a non-mammalian system |
| EP2417982A1 (en) * | 2010-07-30 | 2012-02-15 | Ferring B.V. | Stabilization of gonadotropins |
| US20150376228A1 (en) * | 2013-02-22 | 2015-12-31 | Biogenomics Limited | Process for high efficiency refolding of recombinant proteins |
| WO2017019776A1 (en) * | 2015-07-27 | 2017-02-02 | Purdue Research Foundation | Tandem folding methods to improve protein folding yield |
| EP3344651B1 (en) | 2015-09-02 | 2022-03-02 | Merck Sharp & Dohme Corp. | A process for obtaining insulin with correctly formed disulfide bonds |
| IL285146B (en) * | 2016-07-22 | 2022-09-01 | Amgen Inc | Methods for purifying proteins involving fc |
| CN108276470A (zh) * | 2017-01-06 | 2018-07-13 | 深圳市新产业生物医学工程股份有限公司 | 细胞裂解液、提取胞内蛋白的方法、制备弓形虫抗原的方法和试剂盒 |
| US11406576B2 (en) * | 2017-04-10 | 2022-08-09 | Kao Corporation | Method for removing keratotic plugs |
| CN119881293A (zh) | 2018-03-21 | 2025-04-25 | 沃特世科技公司 | 基于非抗体高亲和力的样品制备、吸附剂、装置和方法 |
| KR20210110294A (ko) * | 2018-11-07 | 2021-09-07 | 어플라이드 몰레큘라 트랜스포트 인크. | 통과세포외배출용 전달 구조체 및 관련 방법 |
| AU2021399935A1 (en) | 2020-12-18 | 2023-06-29 | Richter Gedeon Nyrt. | Methods for the purification of refolded fc-peptide fusion protein |
| CN115894604B (zh) * | 2022-12-16 | 2024-01-23 | 康日百奥生物科技(苏州)有限公司 | 重组蛋白澄清纯化方法 |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4468464A (en) | 1974-11-04 | 1984-08-28 | The Board Of Trustees Of The Leland Stanford Junior University | Biologically functional molecular chimeras |
| US4237224A (en) | 1974-11-04 | 1980-12-02 | Board Of Trustees Of The Leland Stanford Jr. University | Process for producing biologically functional molecular chimeras |
| EP0122080B1 (en) | 1983-03-25 | 1989-09-13 | Celltech Limited | A process for the production of a protein |
| US4468454A (en) | 1983-06-10 | 1984-08-28 | E. I. Du Pont De Nemours And Company | Antifoggant process |
| US4572798A (en) * | 1984-12-06 | 1986-02-25 | Cetus Corporation | Method for promoting disulfide bond formation in recombinant proteins |
| GB8508340D0 (en) | 1985-03-29 | 1985-05-09 | Creighton T E | Production of protein |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| CA1339757C (en) | 1987-04-16 | 1998-03-17 | Robert F. Halenbeck | Production of purified biologically active, bacterially produced recombinant human csf-1 |
| IL86090A (en) | 1987-04-16 | 1993-03-15 | Cetus Oncology Corp | Production of purified, biologically active, bacterially produced recombinant human csf-1 |
| CA1329119C (en) | 1988-03-29 | 1994-05-03 | Milton David Goldenberg | Cytotoxic therapy |
| GB8807673D0 (en) | 1988-03-31 | 1988-05-05 | Lingner & Fischer Gmbh | Novel article |
| EP0719860B1 (en) | 1988-05-13 | 2009-12-16 | Amgen Inc. | Process for isolating and purifying G-CSF |
| GB8927546D0 (en) * | 1989-12-06 | 1990-02-07 | Ciba Geigy | Process for the production of biologically active tgf-beta |
| US5986070A (en) | 1990-04-06 | 1999-11-16 | Amgen Inc. | Production of biologically active NGF proteins |
| EP0547102B1 (en) * | 1990-09-05 | 1998-07-08 | Southern Cross Biotech Pty.Ltd. | Solubilization of proteins in active forms |
| WO1993018136A1 (en) | 1992-03-05 | 1993-09-16 | Cytomed, Inc. | Process for supporting hematopoietic progenitor cells |
| US5663304A (en) | 1993-08-20 | 1997-09-02 | Genentech, Inc. | Refolding of misfolded insulin-like growth factor-I |
| ES2096416T3 (es) | 1993-11-10 | 1997-03-01 | Pfizer | Procedimiento para el repliegue de proquimosina que comprende el reciclado de urea. |
| US5466377A (en) | 1994-01-19 | 1995-11-14 | Grandics; Peter | Chromatography media and their uses |
| IL113497A (en) | 1994-04-28 | 2001-01-11 | Amgen Inc | Method for controlling metallophosphate precipitation in high cell density fermentations |
| AU2603995A (en) | 1994-05-25 | 1995-12-18 | University Of Nebraska Board Of Regents | Biologically active glycoprotein hormones produced in procaryotic cells |
| WO1996040912A1 (en) | 1995-06-07 | 1996-12-19 | Amgen Inc. | Ob protein compositions and method |
| ATE301672T1 (de) | 1996-01-23 | 2005-08-15 | Ortho Mcneil Pharm Inc | Methode zur reinigung eines erythrpoietinbindenden proteins |
| US5935824A (en) | 1996-01-31 | 1999-08-10 | Technologene, Inc. | Protein expression system |
| US20020052026A1 (en) | 1997-10-08 | 2002-05-02 | Steven M. Vicik | Methods of refolding proteins |
| US6180391B1 (en) | 1998-01-28 | 2001-01-30 | Amgen Inc. | Highly efficient controlled expression of exogenous genes in e. coli |
| US6653098B1 (en) * | 1998-02-23 | 2003-11-25 | G. D. Searle & Co. | Method of producing mouse and human endostatin |
| DK1066380T3 (da) | 1998-05-19 | 2002-01-28 | Avidex Ltd | Opløselig T-cellereceptor |
| US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| MXPA02000680A (es) | 1999-07-21 | 2002-07-02 | Amgen Inc | Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf. |
| US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
| NZ522847A (en) | 2000-05-16 | 2004-11-26 | Bolder Biotechnology Inc | Methods for refolding proteins containing free cysteine residues |
| CA2421588C (en) | 2000-09-05 | 2010-01-26 | Amgen Inc. | Tnf receptor-like molecules and uses thereof |
| CZ20032208A3 (cs) | 2001-02-23 | 2004-01-14 | Immunex Corporation | Zvýšený výtěžek aktivních proteinů |
| US6972327B1 (en) | 2001-05-08 | 2005-12-06 | Immunex Corporation | Regeneration of chromatography material |
| US7138370B2 (en) * | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
| ITMI20012345A1 (it) | 2001-11-08 | 2003-05-08 | Internat Ct For Genetic En Gin | Procedimento per la produzione di interferone alfa di grado terapeutico |
| SI21102A (sl) | 2001-12-19 | 2003-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Postopek za izolacijo biološko aktivnega granulocitne kolonije stimulirajočega dejavnika |
| WO2004001056A1 (en) | 2002-06-24 | 2003-12-31 | Dr. Reddy's Laboratories Ltd. | Process for preparing g-csf |
| US7067279B1 (en) | 2002-08-23 | 2006-06-27 | Immunex Corporation | Cell culture performance with betaine |
| EP2272864A3 (en) | 2002-12-20 | 2011-02-16 | Amgen Inc. | Binding agents which inhibit myostatin |
| US7083948B1 (en) | 2002-12-24 | 2006-08-01 | Immunex Corporation | Polypeptide purification reagents and methods for their use |
| EP1449848A1 (en) | 2003-02-20 | 2004-08-25 | GBF German Research Centre for Biotechnology | Method for the production of cystine-knot proteins |
| GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| ATE462716T1 (de) | 2003-10-24 | 2010-04-15 | Amgen Inc | Verfahren zur aufreinigung von proteinen in einer durchflussfraktion aus der chromatographie mit hydrophoben wechselwirkungen |
| CA2554929A1 (en) | 2004-01-30 | 2005-08-18 | Amgen Inc. | Process for purifying proteins |
| MXPA06008812A (es) | 2004-02-04 | 2008-03-07 | Neose Technologies Inc | Metodo de replegamiento de glicosiltransferasas de mamiferos. |
| US20050209441A1 (en) | 2004-03-22 | 2005-09-22 | Lile Jackson D | Process for promoting proper folding of human serum albumin using a human serum albumin ligand |
| FR2874318B1 (fr) | 2004-08-19 | 2006-11-24 | Oreal | Utilisation en cosmetique de composes polysaccharidiques amphoteres a chaine(s) polymerique(s) cationique(s) |
| ATE472333T1 (de) | 2004-08-19 | 2010-07-15 | Biogen Idec Inc | Rückfaltung von proteinen der transforming-growth-factor-beta-familie |
| DE102004041639A1 (de) | 2004-08-27 | 2006-03-02 | Bioceuticals Arzneimittel Ag | Verfahren zur Gewinnung von biologisch aktivem humanen G-CSF aus Inclusion Bodies |
| WO2006036834A2 (en) | 2004-09-24 | 2006-04-06 | Amgen Inc. | MODIFIED Fc MOLECULES |
| US7435804B2 (en) | 2004-10-19 | 2008-10-14 | Phage Biotechnology, Inc. | Method for obtaining single chain antibodies to human interferon α2b |
| WO2006047340A2 (en) | 2004-10-22 | 2006-05-04 | Amgen Inc. | Methods for refolding of recombinant antibodies |
| CA2592261C (en) | 2004-12-10 | 2015-11-24 | Zymogenetics Inc. | Fgf18 production in prokaryotic hosts |
| ES2579758T3 (es) | 2005-01-28 | 2016-08-16 | Zymogenetics, Inc. | Preparaciones homogéneas de IL-31 |
| US20080171857A1 (en) | 2005-03-17 | 2008-07-17 | Uma Devi Komath | Process for the Purification of Recombinant Granulocyte-Colony Stimulating Factor |
| US7344962B2 (en) | 2005-06-21 | 2008-03-18 | International Business Machines Corporation | Method of manufacturing dual orientation wafers |
| DE102005033250A1 (de) | 2005-07-15 | 2007-01-18 | Bioceuticals Arzneimittel Ag | Verfahren zur Reinigung von G-CSF |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| WO2007059494A2 (en) | 2005-11-14 | 2007-05-24 | Amgen, Inc. | Thermally insulated apparatus for liquid chromatographic analysis |
| EP1963367A4 (en) | 2005-12-06 | 2009-05-13 | Amgen Inc | POLISHING STEPS IN MULTI-STAGE PROTEIN PURIFICATION TREATMENTS |
| EP2336164A1 (en) | 2005-12-22 | 2011-06-22 | Genentech, Inc. | Recombinant production of heparin binding proteins |
| US7612273B2 (en) * | 2006-03-20 | 2009-11-03 | Roland Corporation | Electronic percussion instrument |
| EP1845103B1 (en) * | 2006-04-10 | 2015-02-25 | Boehringer Ingelheim RCV GmbH & Co KG | Method for refolding a protein |
| WO2007147019A2 (en) | 2006-06-13 | 2007-12-21 | Zymogenetics, Inc. | Il-17 and il-23 antagonists and methods of using the same |
| WO2008008975A2 (en) | 2006-07-14 | 2008-01-17 | Genentech, Inc. | Refolding of recombinant proteins |
| WO2008011132A2 (en) | 2006-07-21 | 2008-01-24 | Amgen, Inc. | Rupture valve |
| WO2008097829A2 (en) | 2007-02-02 | 2008-08-14 | Neose Technologies, Inc. | Large scale production of eukaryotic n-acetylglucosaminyltransferase i in bacteria |
| PE20090722A1 (es) | 2007-02-02 | 2009-07-13 | Amgen Inc | Hepcidina, antagonistas de la hepcidina y metodos de uso |
| WO2008096370A2 (en) | 2007-02-05 | 2008-08-14 | Natco Pharma Limited | An efficient and novel purification method of recombinant hg-csf |
| US20080214795A1 (en) * | 2007-02-14 | 2008-09-04 | Amgen Inc. | Method of isolating antibodies by precipitation |
| BRPI0815416A2 (pt) | 2007-08-15 | 2014-10-21 | Amunix Inc | Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos |
| EP2262835A1 (en) | 2008-02-29 | 2010-12-22 | Ramot at Tel-Aviv University Ltd. | Immunoglobulin compositions and methods of producing same |
| PT2307454T (pt) | 2008-06-25 | 2017-04-26 | Esbatech Alcon Biomed Res Unit | Anticorpos estáveis e solúveis que inibem o vegf |
| JP5808323B2 (ja) | 2009-06-22 | 2015-11-10 | アムジエン・インコーポレーテツド | 化学的に制御されたレドックス状態を用いたタンパク質のリフォールディング |
| EP3660032B1 (en) * | 2009-06-25 | 2025-10-22 | Amgen Inc. | Capture purification processes for proteins expressed in a non-mammalian system |
| TWI648532B (zh) | 2011-08-29 | 2019-01-21 | 美商安美基公司 | 用於非破壞性檢測-流體中未溶解粒子之方法及裝置 |
| US8945872B2 (en) | 2013-01-25 | 2015-02-03 | Warsaw Orthopedic, Inc. | Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein |
| CN105530949A (zh) | 2013-03-15 | 2016-04-27 | 安姆根有限公司 | 人类受试者中的肌抑素拮抗作用 |
| US9632095B2 (en) | 2014-12-01 | 2017-04-25 | University Of Delaware | Device and method for determining reaction kinetics |
| US9704239B1 (en) | 2016-09-02 | 2017-07-11 | Amgen Inc. | Video trigger synchronization for improved particle detection in a vessel |
-
2010
- 2010-06-21 JP JP2012517634A patent/JP5808323B2/ja active Active
- 2010-06-21 BR BRPI1011940A patent/BRPI1011940B8/pt active IP Right Grant
- 2010-06-21 US US12/820,087 patent/US8952138B2/en active Active
- 2010-06-21 EP EP18167168.6A patent/EP3366692A1/en active Pending
- 2010-06-21 KR KR1020127001716A patent/KR101741859B1/ko active Active
- 2010-06-21 WO PCT/US2010/039390 patent/WO2011005488A1/en not_active Ceased
- 2010-06-21 CA CA2765881A patent/CA2765881C/en active Active
- 2010-06-21 EP EP10747092.4A patent/EP2445923B1/en active Active
- 2010-06-21 EA EA201270015A patent/EA020621B1/ru not_active IP Right Cessation
- 2010-06-21 MX MX2011013898A patent/MX2011013898A/es active IP Right Grant
- 2010-06-21 CN CN201080028756.7A patent/CN102482321B/zh active Active
- 2010-06-21 SG SG2011095411A patent/SG176963A1/en unknown
- 2010-06-21 AU AU2010270986A patent/AU2010270986B2/en active Active
-
2011
- 2011-12-13 IL IL216954A patent/IL216954A/en active IP Right Grant
- 2011-12-22 CL CL2011003278A patent/CL2011003278A1/es unknown
-
2012
- 2012-01-20 ZA ZA2012/00512A patent/ZA201200512B/en unknown
-
2015
- 2015-01-30 US US14/611,037 patent/US20150315232A1/en not_active Abandoned
- 2015-07-07 US US14/793,590 patent/US20150329586A1/en not_active Abandoned
- 2015-09-07 JP JP2015175422A patent/JP6026608B2/ja active Active
-
2017
- 2017-02-01 US US15/422,327 patent/US9856287B2/en active Active
-
2018
- 2018-02-06 US US15/889,559 patent/US12269843B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1011940B8 (pt) | método de redobramento de uma proteína expressa em um sistema de expressão de não mamífero | |
| AR088513A1 (es) | Inmunoenlazantes dirigidos contra esclerostina | |
| PE20081655A1 (es) | Medios racionalmente disenados para cultivo celular | |
| BR112016023304A2 (pt) | célula hospedeira recombinante engendrada para superexpressar proteínas auxiliares | |
| BR112012028805A2 (pt) | composições de endorribonuclease e métodos de uso das mesmas. | |
| AR076541A1 (es) | Mutantes de fgf21 y usos del mismo | |
| BR112015022322A2 (pt) | sistemas e métodos para detecção de células com o uso de partículas de transdução projetadas | |
| CL2007001488A1 (es) | Anticuerpo humano o humanizado anti-integrina alfa5beta1; acido nucleico que lo codifica; vector y celula huesped que lo comprenden; procedimiento de produccion; composicion farmaceutica que lo comprende; y su uso para prevenir o tratar trastornos asociados con la integrina. | |
| BR112012001984B8 (pt) | anticorpos humanos com alta afinidade para angiopoietina-2 humana, uso dos mesmos e composição farmacêutica | |
| CO6470854A2 (es) | Variantes de celulasa con expresión, actividad y/o estabilidad mejoradas, y uso de las mismas | |
| BR122019022434B8 (pt) | método para cultivar células de mamífero que secretam proteína heteróloga em um sobrenadante de cultura celular | |
| MX2020003168A (es) | Pirimidinas modificadas en la posicion 5 y su uso. | |
| BR112014006244A2 (pt) | microrganismos e métodos para produzir alcenos | |
| CL2013002361A1 (es) | Metodo para medir actividad de células natural killer (nk); kit para medir dicha actividad; proteína de fusión; composicion para activar células nk; polipéptido, oligonucleótido, vector y célula hospedera que comprenden la proteína; | |
| BR112013007862A2 (pt) | ácidos nucleicos manipulados e métodos de uso dos mesmos. | |
| BR112016015677A2 (pt) | Moléculas de anticorpo isoladas capazes de se ligarem à pd-1 humana, bem como seu método de produção e seu uso, composições farmacêuticas, ácido nucleico, vetor de expressão, célula hospedeira, e método para detecção de pd-1 em uma amostra biológica | |
| BR112015022210A8 (pt) | formulações de anticorpo | |
| UY33802A (es) | Composiciones inmunógenas que comprenden un antígeno relacionado con M72 y que tienen una fuerza iónica baja | |
| BR112015004467A2 (pt) | método para controlar a heterogeneidade de proteínas | |
| CL2008001675A1 (es) | Dominio variable simple (dab) de inmunoglobulina anti-factorde crecimiento endotelial vascular (vegf); acido nucleico que lo codifica; vector y celula huesped; metodo de produccion;antogonista de vegf que comprende el dab; composicion que comprende antogonista;y uso del antagonista para preparar un medicamento. | |
| BR112014006511A2 (pt) | atividade de dnase endógena para reduzir teor de dna | |
| EP2634252A3 (en) | Method of expressing proteins with disulfide bridges | |
| BR112015017977A8 (pt) | método de cultura líquida, método para obter e/ou cultivar uma cripta, cripta, usos da cripta | |
| BR112013021836A2 (pt) | plantas que possuem características relativas a rendimento aprimoradas e métodos de sua produção | |
| BR112015013421A2 (pt) | célula hospedeira microbiana transgênica, polipeptídeo isolado, métodos de produção de um polipeptídeo e de uma proteína, processos de degradação de um material celulósico, de produção de um produto de fermentação e de fermentação de um material celulósico, construção de ácido nucleico ou vetor de expressão, polipeptídeo isolado, e polinucleotídeo isolado |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.21 NA RPI NO 2564 DE 27/02/2020 POR TER SIDO INDEVIDA. |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/07/2021, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REF. RPI 2637 DE 20/07/2021 QUANTO AO PRAZO DE VALIDADE. |